Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial
Juanita Lopez(Institute of Cancer Research), Christoph Petry(CS Diagnostics), Jeffrey Yachnin(Karolinska University Hospital), Claire F. Friedman(Memorial Sloan Kettering Cancer Center), Jingbin Zhang(Roche (Canada)), Vincent J. P. Leveque, Michael Gordon(Monash Health), Ryan J. Sullivan(Dana-Farber Cancer Institute), Leesun Kim(Ulsan National Institute of Science and Technology), Luc Dirix(GZA Ziekenhuizen Campus Sint-Augustinus), Rachel Lubong Sabado(Tisch Hospital), Ioannis Karydis(University Hospital Southampton NHS Foundation Trust), Kit Man Wong(University of Washington), Ignacio Melero(University of Oxford), Gautham K. Rao(Bristol-Myers Squibb (United States)), Martine Darwish, George A. Fisher(Stanford University), Mahesh Yadav(University of Florida), Martin Schüler(German Cancer Research Center), Vladimir Galvao(Hebron University), Aglaia Schiza(Uppsala University Hospital), Patrick A. Ott(Dana-Farber Cancer Institute), Achim Rittmeyer(Unknown), Ina Rhee, Neeltje Steeghs(Peter MacCallum Cancer Centre), Ani Sarkis Balmanoukian(Angeles Clinic and Research Institute), Ting Qi(University of Chinese Academy of Sciences), Marcus Schmidt(Johannes Gutenberg University Mainz), Rom S. Leidner(Providence Portland Medical Center), Patricia LoRusso(Yale Cancer Center), Gregg Fine(Genesys (United States)), Jiawen Zhu(Marine Biomedical Research Institute of Qingdao), Guy Jérusalem(Centre Hospitalier Universitaire de Liège), Lars Müller(Gilead Sciences (United States)), Howard A. Burris(Deaconess Hospital), Lawrence Fong(UCSF Helen Diller Family Comprehensive Cancer Center), Scott A. Laurie(Ottawa Hospital), Eelke Gort(University Medical Center Utrecht), Brian S. Henick(NewYork–Presbyterian Hospital), Alberto Robert, Sylvie Rottey(Ghent University Hospital), Dirk Jaeger(Heidelberg University), Thomas Powles(Queen Mary University of London), Fadi Braiteh(Opexa Therapeutics (United States)), Patrick Twomey(AbbVie (United States)), Michael R. Mancuso(Stanford Medicine), Lillian L. Siu(University Health Network), Raid Aljumaily(Sarah Cannon)
Cited by 104
Related Papers
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k